DataMeds outlines peptide compounding plans after FDA policy proposal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to DataMeds outlines peptide compounding plans after FDA policy proposal

DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap

October 16, 2026 6:01 AM EDT

TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ: MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx and smart contracts platform PharmacyChain, today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled "Interim Access Policy for Compounding Using... More